References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: Cancer J Clin. 2015 Jan–Feb;65:5–29.
- Leto SM, Trusolino L. Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. J Mol Med. 2014 Jul;92(7):709–22. doi:10.1007/s00109-014-1161-2. Epub 2014 May 10.
- Tonini G, Imperatori M, Vincenzi B, Frezza AM, Santini D. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res. 2013 Nov 18;32:92. doi:10.1186/1756-9966-32-92. Review.
- Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol. 2012 Sep;23(9):2313–8. doi:10.1093/annonc/mdr623. Epub 2012 Mar 5.
- Update European Society for Medical Oncology (ESMO) Clinical Practice guidelines 2014.
- Clarke JM, Hurwitz HI, Rangwala F. Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician’s perspective. Cancer Treat Rev. 2014 Oct;40(9):1065–72. doi:10.1016/j.ctrv.2014.07.001. Epub 2014 Jul 11. Review.
- Artale S, Sartore-Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol. 2008 Sep 1;26(25):4217–9. doi:10.1200/JCO.2008.18.7286. No abstract available.
- Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3’ kinase/AKT pathways. Oncogene. 2005 Nov 14;24(50):7443–54. Review.10.1038/sj.onc.1209091
- Maindrault-Goebel F, Tournigand C, André T, Carola E, Mabro M, Artru P, et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol. 2004 Aug;15(8):1210–4.10.1093/annonc/mdh305
- Townsend AR, Bishnoi S, Broadbridge V, Beeke C, Karapetis CS, Jain K, et al. Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. Am J Clin Oncol. 2013 Feb;36(1):49–52. doi:10.1097/COC.0b013e31823fe40e.
- Suenaga M, Mizunuma N, Matsusaka S. A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and irinotecan for advanced colorectal cancer (RE-OPEN study). J Clin Oncol. 2013;31 (suppl 4; abstr 580).
- Santini D, Vincenzi B, La Cesa A, Caricato M, Schiavon G, Spalletta B, et al. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. Oncology. 2005;69(1):27–34. Epub 2005 Jul 28.10.1159/000087285
- Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):303–12. doi:10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22.
- Kidd MT, Wilcox RE, Rogers J, Eng C, Saadat S, Lenz HJ, et al. Efficacy of chemotherapy after treatment with regorafenib in metastatic colorectal cancer (mCRC). J Clin Oncol. 2015;33 (suppl 3; abstr 678).
- Marks E, Tan C, Zhang J, Zhou L, Yang Z, Scicchitano A, et al. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biol Ther. Published online 2015 Nov;16(12):1710–9 doi:10.1080/15384047.2015.1113355.